Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATE versus NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATE versus NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE.
NEOMYCIN AND POLYMYXIN B SULFATE vs NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B sulfate is a cationic detergent that disrupts bacterial cell membrane permeability by interacting with phospholipids, leading to cell death.
Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane integrity, and interfere with cell wall synthesis, respectively. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
For irrigation of urinary bladder: 1 mL of solution containing 40 mg neomycin and 200,000 units polymyxin B per mL diluted in 1 liter of 0.9% sodium chloride, instilled via continuous irrigation at a rate of 1 liter per 24 hours. For topical use: apply thin layer to affected area 2-4 times daily.
Apply to affected area 3-4 times daily. Not for use in eyes.
None Documented
None Documented
Neomycin: 2-3 hours (normal renal function), prolonged to 24-48 hours in renal impairment; Polymyxin B: 4.5-6 hours (normal renal function), extended significantly in renal failure.
Neomycin: 2-3h (normal renal); polymyxin B: 4-6h (normal renal), prolonged to 2-3 days in renal impairment; bacitracin: ~1.5h after IM; hydrocortisone: 1.5-2h (plasma). Topical: systemic levels negligible.
Renal: ~90-95% (neomycin, polymyxin B) unchanged; fecal: 5-10% (biliary excretion negligible).
Neomycin: >90% renal (unchanged) after parenteral; polymyxin B: ~60% renal (unchanged) over 72h; bacitracin: >90% renal (unchanged) after IM; hydrocortisone: hepatic metabolism, metabolites renally eliminated (<1% unchanged). Topical: negligible systemic absorption across intact skin (except bacitracin may be minimally absorbed).
Category A/B
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic